Label-free, MALDI-based HTS ‘in a heartbeat’ at 1 second assay time
(~50,000 assays per day) with 100x less solvent cost, and faster assay
development, represents a paradigm change in mass spectrometry-based HTS
ST. LOUIS--(BUSINESS WIRE)--
At the 63rd ASMS Conference on Mass Spectrometry and Allied
Topics, Bruker (NASDAQ: BRKR) today announced a new high-throughput
screening (HTS) solution designed to help pharmaceutical companies
achieve high throughput, lower cost and higher specificity in drug
discovery. The new MALDI PharmaPulse™ solution combines the
speed, sensitivity and ease-of-use of Bruker’s robust MALDI-TOF systems
with industry-leading HTS robotics and automation software from HighRes
Biosolutions, Inc. of Woburn, MA.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20150601005089/en/
The Bruker MALDI PharmaPulse™, helps pharmaceutical companies achieve high throughput, lower cost and higher specificity in drug discovery. (Photo: Business Wire)
The new MALDI PharmaPulse solution is the latest addition to
Bruker’s portfolio of innovative products designed to assist
pharmaceutical, biotech and CRO customers accelerate drug discovery and
development. Based on the autoflex™ speed MALDI TOF
system, and incorporating an integrated automation solution from HighRes
Biosolutions, this new HTS solution offers the fastest commercially
available mass spectrometry-based screening solution with significantly
lower cost per sample. In addition, its label-free detection of
substrates accelerates assay development, reduces complexity of
screening, and potentially minimizes artifacts from interferences with
the labels used in traditional HTS technologies.
The unique capabilities of the novel MALDI PharmaPulse solution
for driving higher throughput at dramatically lower costs for screening
in drug discovery, include:
-
Less than 1 second per sample analysis time, comparable to the pulse
of the human heart, and fast enough for true high throughput screening
(HTS)
-
autoflex speed MALDI TOF equipped with proprietary 2 kHz smartbeam™-II
laser
-
Integrated automation solution from HighRes Biosolutions seamlessly
prepares and feeds MALDI plates from 96, 384 or 1536 assay plates
-
MALDI-detection removes need for SPE cartridges or LC columns, uses
100x less solvent per sample than conventional LC-MS methods
-
Does not require derivatization in comparison to fluorescence workflows
-
Development times for new assays and complexity is dramatically
reduced without the need for chromatographic method development, SPE
or MRM setup, or derivatization protocols
-
The extremely low sample volumes required for detection (typically ~1
µL) enables “Single Well Kinetic Readout” by sampling multiple time
points per assay
-
The full automation, coupled with speed of MALDI TOF, enables the
screening of over 50.000 compounds per day
Due to this unique feature set, the MALDI PharmaPulse enables
pharmaceutical customers to accelerate their drug discovery efforts with
higher throughput assays, delivering higher quality results while
lowering costs.
Dr. Paul Speir, Senior Vice President for the Americas of the Bruker
Daltonics division, stated: “The unique MALDI PharmaPulse solution
was developed in close collaboration with leading HTS scientists in the
pharmaceutical industry. These types of collaborative projects enable
Bruker to deliver integrated solutions that truly meet the emerging
needs of pharma customers looking for breakthroughs.”
About Bruker Corporation
For more than 50 years, Bruker has
enabled scientists to make breakthrough discoveries and develop new
applications that improve the quality of human life. Bruker’s
high-performance scientific research instruments and high-value
analytical solutions enable scientists to explore life and materials at
molecular, cellular and microscopic levels.
In close cooperation with our customers, Bruker is enabling innovation,
productivity and customer success in life science molecular research, in
applied and pharma applications, and in microscopy, nano-analysis and
industrial applications, as well as in cell biology, preclinical
imaging, clinical research, microbiology and molecular diagnostics. For
more information, please visit: http://www.bruker.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150601005089/en/
Source: Bruker Corporation